Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, announced that the company is presenting results from a...
Engimmune Therapeutics AG ("Engimmune"), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, announced the completion of a CHF 15.5 million (EUR 15.2...
BeiGene, Ltd., a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, announced...
Debiopharm, an oncology and infectious disease focused biopharmaceutical company based in Switzerland, today announced data releases on 3 investigational products including Debio 0123 (Selective...
